article thumbnail

Pharma firepower, M&A surge last year bode well for dealmaking prospects in 2024: EY

Fierce Pharma

In it’s annual Firepower report, EY says the biopharma industry enters 2024 with the capability and motivation to increase M&A activity. The late surge of activity in 2023 also bodes well for a 2024 uptick, the group said. Morgan Healthcare Conference. |

article thumbnail

Why Provider Groups Are Denouncing CMS’ New Payment Rules

MedCity News

CMS finalized updates to its physician fee schedule for 2024, as well as finalized the rule for next year’s Outpatient Prospective Payment System (OPPS). Provider groups are displeased with the updated rules, arguing that both physicians and provider organizations need more monetary relief than what the agency is offering.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Biopharma dealmaking: predictions for 2024

European Pharmaceutical Review

This activity is expected to continue in 2024, with increasing need for biopharma to access innovation through collaboration and dealmaking to offset looming patent challenges. “In Referencing the EY Firepower report 2023 , Baral highlights several key fundamentals that point to increased dealmaking in 2024.

Biopharma 105
article thumbnail

AI and automation to drive “substantial progress” in pharmaceutical analytical testing

European Pharmaceutical Review

percent between 2024 and 2032. percent market share between 2024 and 2032, based on the forecast by Straits Research. Their analysis projected that the market will exceed a value of $15.46 billion by 2032. The market is furthermore expected to see a compound annual growth rate (CAGR) of 7.3

article thumbnail

Industry Outlook 2025: Through the Lens of a Service Provider

PharmaTech

Pharmaceutical Technology spoke with Adam Sherlock, CEO of Qinecsa, about the industry trends of 2024, the future technology agenda, and M&A prospects in 2025.

article thumbnail

Choosing the Right Prospects: A Sales Rep’s Guide

Pharmaceutical Representative Training

Identifying and engaging the right prospects can make all the difference between success and stagnation, making it crucial to driving sales growth. 2 By honing in on the right prospects and understanding their needs, you can enhance their effectiveness and meet their sales goals more efficiently. So what is an ICP?

article thumbnail

Launch Readiness 2024: A fresh look at key trends affecting pharma product launches

Tribeca Knowledge

I n our latest report, Launch Readiness 2024 , we look at the prospects and obstacles facing new medicines in markets still recovering from the COVID-19 pandemic.